Earnings

CareDx Raises 2026 Revenue Outlook After Naveris Acquisition

The Tip Desk · November 10, 2026 · 3 min read

Third-quarter revenue was $139 million, up 39% from a year earlier, and the company now expects full-year 2026 sales of $520 million to $530 million.

CareDx, Inc. (CDNA), a precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, reported third-quarter revenue of $139 million, up 39% from $100 million a year earlier, after 52% year-over-year growth in the second quarter.

The company said the increase was driven primarily by Testing Services and Patient and Digital Solutions, including Specialty Oncology revenue added after it closed the Naveris, Inc. acquisition on July 1, 2026 for $160 million in cash and up to $100 million in contingent consideration. Third-quarter results no longer include the Lab Products business, which CareDx sold on June 30, 2026.

Testing Services revenue was $119 million, up 65% from $72 million a year earlier, including $12 million in Specialty Oncology revenue. Testing Services volume was approximately 75,900, up 51% year-over-year, including Specialty Oncology contributions. The company said Testing Services revenue included $15 million in prior-period revenue, compared with $6 million a year earlier. Excluding that prior-period recognition, Testing Services revenue increased approximately 58% year-over-year.

Patient and Digital Solutions revenue was $20 million, up 31% from $15 million a year earlier, which the company attributed primarily to continued growth in CareDx Pharmacy services.

GAAP net income was $19 million, or $0.35 a share diluted, compared with $2 million, or $0.03 a share diluted, in the third quarter of 2025. GAAP net income margin was approximately 14%, compared with approximately 2% a year earlier. Adjusted EBITDA was $30 million, compared with $15 million a year earlier, for an adjusted EBITDA margin of approximately 22%, compared with approximately 15%. The company said the adjusted EBITDA increase was driven by revenue growth, higher gross profit and disciplined operating expense management. Cash flow from operations was $13 million.

Cash and cash equivalents were $250 million as of September 30, 2026, compared with $65 million at year-end 2025, after the company had $112 million in current marketable securities at year-end. Intangible assets, net, were $140 million and goodwill $122 million at quarter-end, versus $32 million and $40 million at year-end 2025.

CareDx now expects full-year 2026 revenue of $520 million to $530 million, compared with a previously disclosed range of $490 million to $500 million. Full-year 2026 adjusted EBITDA guidance is now $90 million to $100 million, compared with a prior range of $66 million to $78 million.

President and Chief Executive Officer John Hanna said the company delivered continued growth in Transplant, progress scaling Specialty Oncology, and advances across the pipeline and clinical evidence, including in Cell Therapy. The company said it advanced AlloHeme toward a planned first-quarter 2027 commercial launch and HistoMap Kidney toward broader commercial availability in 2027, with both programs targeting CLIA readiness before year-end. It also said more than 5,000 transplant patients were registered for the new CareDx patient portal and that NavDx was migrated to the CareDx billing platform.

Hanna said the company sees significant clinical interest in how molecular information can inform more decisions across a patient’s care journey and that it believes those dynamics create meaningful opportunities for continued profitable growth.

More on CDNA

September 28, 2026 QBook Stronger demand supports expansion as pricing diverges

CareDx, Inc. — all coverage and financials